OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017

Reportstack has announced a new market report on OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017. Late-stage chronic kidney disease (CKD), encompassing stage 4 and 5 CKD, is a disease that manifests in a host of co-morbidities. Of these, bone and mineral metabolism disorders are some of the most commonly treated and have significant impact on morbidity and mortality of patients. This report focuses on the current treatment landscape, unmet needs, pipeline and remaining opportunity in the late-stage CKD market with a focus on the treatment of hyperphosphatemia and secondary hyperparathyroidism (SHPT). This changeable landscape is a consequence of a number of contributory factors, including the patent expiries of market leading hyperphosphatemia brands, and the expected launch of three new entrants to the market. 

Scope
- Overview of late-stage CKD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Topline late-stage CKD therapeutics market revenue from 2012–2017.  
   Annual cost of therapy, and major marketed and pipeline drug sales in this forecast period are included.
- Key topics covered include strategic competitor assessment, market
   characterization, unmet needs, R&D strategies, and clinical trial design  
   for the late-stage CKD therapeutics market.
- Pipeline analysis: comprehensive data split across different phases,
  emerging novel trends under development, synopses of innovative
   early-stage projects, and detailed analysis of late-stage pipeline drugs. 
   An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global
   late-stage CKD therapeutics market. Insightful review of the key industry
  drivers, restraints and challenges. Each trend is independently
 researched to provide qualitative analysis of its implications.

Key Findings
The late-stage CKD therapeutics market (hyperphosphatemia and SHPT), in the 6MM is forecasted to decline from $1.88bn in 2012 to $1.66bn in 2017, at a CAGR of -2.5%. This decline is attributed to the loss of patent protection for major brands and tightening reimbursement environment for oral treatments in dialysis patients.
With the expected launch of three novel pipeline agents, the dialysis CKD market segment is due to become increasingly competitive over the forecast period as these agents enter a heavily genericized market.
Interviewed experts report pipeline agents to have clinical advantages and expect them to partially address some key unmet needs. Remaining opportunities will be seized by future players who invest in considerable innovations through agents with novel mechanism of actions.

Key Benefits
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global late-stage CKD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global late-stage CKD therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

List of Companies in this report are AbbVie, Amgen, Ardelyx, Deltanoid Pharmaceuticals, Fresenius Medical Care, Galenica, Keryx Biopharmaceuticals, Mitsubishi Pharma Europe, Nektar Therapeutics, OPKO Health, Sanofi/Genzyme, Shield Therapeutics, Shire Pharmaceuticals, Spectrum Pharmaceuticals, Vidasym, Vifor Pharmaceuticals.

To view the table of contents and know more details please visit  OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017  report.